Lilly Just Spent $20 Billion Hunting For Its Next Blockbuster Drug

Eli Lilly is the most valuable drugmaker on the planet right now.

Their blockbuster drugs Zepbound and Mounjaro are printing cash, helping push the stock to one of the best runs in the S&P 500 over the past few years.

And they just spent $20 billion buying other companies.

That's the strange part. Why would a company at the top of its game spend that much money looking for the next thing?

Lilly's Buying Spree

Lilly didn't buy one company - they bought a stack of them.

The money has gone toward biotech firms working on drugs Lilly doesn't already have, including cancer treatments, sleep medicines, vaccines, and gene therapies.

The strategy looks less like a bet on any one drug and more like buying a lot of lottery tickets at once.

That's how Big Pharma usually plays it. Most experimental drugs fail, but the ones that work pay for the rest many times over.

We break down deals like this in Market Briefs every weekday morning - and a free 45-minute investing masterclass comes with it.

The Patent Cliff Is Coming

Lilly's weight-loss drugs are still in their prime, with Zepbound and Mounjaro pulling in record sales and reshaping how doctors treat obesity.

But the clock is ticking on Lilly's GLP-1 drugs - a class of medicines that mimic a gut hormone to control hunger and blood sugar.

The main tirzepatide patent expires in 2036, opening the door for cheaper copycats to undercut Lilly on price.

Pharma calls this the patent cliff. Revenue from a blockbuster drug can drop 80% or more within a year of generics hitting the shelves.

Lilly has roughly ten years to find the next thing, and twenty billion buys a lot of shots on goal.

What To Watch

The real test isn't the $20 billion - it's what comes out the other side.

Investors will be watching late-stage drug trials from Lilly's newly acquired pipelines over the next few years, where just one hit the size of Zepbound would cover every deal Lilly just signed.

Miss on all of them, and the next decade looks a lot harder.

Lilly has until the mid-2030s to find it.

Join 350,000+ investors getting Market Briefs in their inbox each morning - and grab the free investing course thrown in as a bonus.